" class="no-js "lang="en-US"> Gilad Almogy - Medtech Alert
Monday, September 29, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Gilad Almogy

Gilad Almogy

About Gilad Almogy

Gilad Almogy founded Ultima Genomics in 2016 with a mission to continuously reduce the cost of sequencing to enable the era of data-driven healthcare, transform biology, and improve human health. Before founding Ultima, Gilad had applied deep technology, engineering, and leadership expertise to push technological boundaries and drive transformation across multiple industries.

Related Story

Artificial Intelligence

 Ultima Genomics Collaborates with NVIDIA To Deliver $100 Genome Sequencing with AI and Accelerated Computing | Pharmtech Focus

Ultima Genomics Collaborates with NVIDIA To Deliver $100 Genome Sequencing with AI and Accelerated Computing

June 8 2022

Ultima Genomics, Inc. today unveiled a broad collaboration with NVIDIA that leverages AI-accelerated analysis across […]